New
Semaglutide
59,95 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
Description
Semaglutide
Weight Loss / Diabetes / Cardiovascular
MECHANISM OF ACTION
GLP-1 analog with 94% homology, featuring a C18 diacid fatty acid chain and two Aib substitutions for DPP-4 resistance. It binds to the GLP-1 receptor (GLP-1R), leading to glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. It has an approximate half-life of 7 days due to binding to albumin. It also reduces neuroinflammation and cardiovascular inflammation.
KEY BENEFITS
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
SIDE EFFECTS AND SAFETY
Nausea, vomiting, and diarrhea—the most common side effects—usually resolve with dose titration. Rare: pancreatitis, gastroparesis, and C-cell thyroid tumors as class warnings. Rapid weight loss can reduce muscle mass; combine with resistance exercise.
RESEARCH AND CLINICAL NOTES
SELECT Trial (2023, NEJM): 20% reduction in MACE in 17,604 overweight subjects without diabetes. STEP Trials: 15–17% reduction in body weight. The most commercially successful peptide in history.
TARGET PROFILE:
Clinical practice in metabolism, cardiovascular medicine, and weight loss.
Additional information
| Weight | ,26 kg |
|---|
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
5-Amino-1MQ
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated lipolysis and fat oxidation without thermogenic effects.
- Improved mitochondrial efficiency and ATP production.
- Supports insulin sensitivity and glucose homeostasis.
- Interest in body recomposition protocols in combination with GLP-1 agonists.
- Supports NAD+ levels relevant to cellular longevity.
New
BPC 157
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated healing of tendons, ligaments, muscles, and connective tissue.
- Protection of the gastrointestinal mucosa and support for ulcer healing.
- Neuroprotection and peripheral nerve regeneration.
- Powerful anti-inflammatory action through the suppression of pro-inflammatory cytokines.
- Systemic cytoprotective effects on multiple organ systems.
- Benefits at SNC: Research on depression, PTSD, and addictive behavior.
New
DSIP
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sleep quality, especially deep, slow-wave (delta) sleep.
- Stress-reducing and anxiolytic effects.
- Normalization of disrupted sleep patterns.
- Potential application in opioid/alcohol withdrawal syndrome.
- Geroprotector: Anticancer Properties in Animal Models.
New
Epithalon
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Telomere elongation and cellular longevity.
- Epigenetic rejuvenation markers in aged tissues.
- Normalization of the circadian rhythm through pineal regulation.
- Cancer Prevention: Tumor-Suppressing Activity in Animal Models.
- Improved skin elasticity, vision, and neuroendocrine function in longevity studies.
- One of the most widely studied anti-aging peptides worldwide.
Glutathione
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Comprehensive reduction of oxidative stress.
- Improved Phase II hepatic detoxification.
- Supports the immune system.
- Skin lightening through the inhibition of melanin synthesis.
- Neuroprotection in Parkinson's disease and other degenerative conditions.
- Improving Insulin Sensitivity in Metabolic Research.
New
PT-141
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sexual desire in men and women.
- Improvement of erectile function via the central nervous system.
- Approved by the FDA for HSDD in premenopausal women as Vyleesi.
- Effective in patients who do not respond to PDE5 inhibitors.
- It can be used as needed, 45–90 minutes before the activity.
Snap-8
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Non-invasive wrinkle reduction equivalent to botulinum toxin, though gentler and safer.
- Reduction in the depth of dynamic wrinkles on the forehead, crow's feet, and glabellar lines.
- Used in conjunction with Matrixyl and GHK-Cu in comprehensive anti-aging regimens.
- Active ingredient for cosmetic formulations or injectable administration.
- The preferred alternative for patients seeking options that do not involve botulinum toxin.
SS-31
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of mitochondrial function in aged and diseased tissues.
- Improved cardiac function in heart failure.
- Renal protection in ischemia-reperfusion injury.
- Reduction of neuroinflammation.
- Preservation of Muscle Fiber in Aging and Sarcopenia.
- FDA Breakthrough Therapy Designation for Barth Syndrome.
